NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been
filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to
request that the court appoint you as lead plaintiff.
Welbilt, Inc. (NYSE: WBT)
Class Period: February 24, 2017 to November 2, 2018
Lead Plaintiff Deadline: February 11, 2019
During the class period, Welbilt, Inc. allegedly made materially false and/or misleading statements and/or
failed to disclose that: (i) the Company lacked effective internal control over financial reporting; (ii) the Company was
incorrectly recording the tax basis of foreign subsidiaries and the amortization of their intangible assets; and (iii) as a result
of the foregoing, Defendants’ statements about Welbilt’s business, operations, and prospects, were false and misleading and/or
lacked a reasonable basis. On November 5, 2018, Welbilt filed a Form 8-K for its Q3 2018, stating that “During the third
quarter of 2018, the Company identified errors in the tax basis of a foreign subsidiary and incorrect amortization of the
intangible assets held by the same entity… In addition, the Company discovered certain intercompany transactions were not recorded
on a timely basis.” As a result of these errors, Welbilt announced that “the consolidated financial statements of the Company as of
and for the year ended December 31, 2016 will be restated, and as of and for the years ended December 31, 2015 and 2017 are
expected to be revised.”
Get additional information about the WBT lawsuit: http://www.kleinstocklaw.com/pslra-1/welbilt-inc-loss-submission-form?wire=3
Nissan Motor Co., Ltd. (OTCMKTS: NSANY)
Class Period: December 10, 2013 to November 16, 2018
Lead Plaintiff Deadline: February 8, 2019
The complaint alleges that during the class period Nissan Motor Co., Ltd. made materially false and/or
misleading statements and/or failed to disclose that: (1) for more than a decade, Nissan had been materially understating its
costs--and thus overstating profits--by paying a material portion of Ghosn’s executive compensation in the form of billions of Yen
of deferred compensation that the Company was concealing from its public financial reports; (2) in so doing, Nissan was concealing
from investors significant defects in its corporate governance; (3) Nissan’s overpayment of defendant Ghosn had caused it to exceed
its shareholder-approved executive pay cap, thus threatening its continued stock listing; (4) Nissan lacked effective internal and
reporting controls; and (5) as a result, defendants’ statements about Nissan’s business metrics, operations, and financial
prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Get additional information about the NSANY lawsuit: http://www.kleinstocklaw.com/pslra-1/nissan-motor-co-ltd-loss-submission-form?wire=3
Tenaris S.A. (NYSE: TS)
Class Period: May 1, 2014 to November 27, 2018
Lead Plaintiff Deadline: February 11, 2019
Throughout the class period, Tenaris S.A. allegedly made materially false and/or misleading statements and/or
failed to disclose that: (1) Tenaris’s CEO and Chairman, Paolo Rocca, knew that one of his company’s executives paid cash to
government officials from 2009 to 2012 to expedite compensation payments for the sale of Sidor; (2) this conduct would lead to
Rocca being charged in a graft scheme, and subject Tenaris, its affiliates, and/or executives to heightened governmental scrutiny;
and (3) as a result, Tenaris’s public statements were materially false and/or misleading at all relevant times. When the true
details entered the market, the lawsuit claims that investors suffered damages.
Get additional information about the TS lawsuit: http://www.kleinstocklaw.com/pslra-1/tenaris-s-a-loss-submission-form?wire=3
Teladoc Health, Inc. (NYSE: TDOC)
Class Period: March 3, 2016 to December 5, 2018
Lead Plaintiff Deadline: February 11, 2019
The lawsuit alleges Teladoc Health, Inc. made materially false and/or misleading statements and/or failed to
disclose during the class period that: (i) Executive Vice President and Chief Operating Officer Mark Hirschhorn was engaged in an
inappropriate sexual relationship with a subordinate; (ii) Hirschhorn and this subordinate engaged in insider trading to provide
themselves with undue benefits; (iii) Hirschhorn caused the subordinate to receive promotions for which she was unqualified,
thereby negatively impacting the Company’s operations; (iv) the Company’s enforcement of its own purported employment and trading
policies were inadequate to prevent the foregoing conduct; and (v) as a result, the Company’s public statements were materially
false and misleading at all relevant times.
Get additional information about the TDOC lawsuit: http://www.kleinstocklaw.com/pslra-1/teladoc-health-inc-loss-submission-form?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or
obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J.
Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud
throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
